The goals of this study were to assess the extent of human intestinal drug transporter
expression, determine the subcellular localization of the drug uptake transporter OATP1A2 …

A new type of interaction in which fruit juices diminish oral drug bioavailability through
inhibition of uptake transport is the focus of this review. The discovery was based on an …

Grapefruit juice produces mechanism‐based inhibition of intestinal drug metabolism when
consumed in normal quantities. This can produce clinically important increases in oral drug …

Objectives The purpose of this study was to elucidate the potential clinical relevance and
mechanism (s) of action of 2 different volumes of grapefruit juice on the reduction of …

Objectives Our objective was to examine the effect of different fruits and their constituents on
P‐glycoprotein and organic anion transporting polypeptide (OATP) activities in vitro and on …

Grapefruit juice is widely recognized to cause important drug interactions via inhibition of
CYP3A4, and a wider variety of fruit juices have been shown to inhibit influx transporters in …

Fexofenadine has been identified as a substrate for both the efflux transporter, P-
glycoprotein (P-gp), as well as the influx transporter, organic anion transporting polypeptide …

Background: Grapefruit juice is known to alter the pharmacokinetics of over 30 prescription
drugs by increasing their bioavailabilities. After the discovery of this interaction almost 20 …

Purpose. Grapefruit juice (GJ) is known to increase the oral bioavailability of many CYP3A-
substrates by inhibiting intestinal phase-I metabolism. However, the magnitude of AUC …

Introduction: Since their initial discovery in 1989, grapefruit juice (GFJ)–drug interactions
have received extensive interest from the scientific, medical, regulatory and lay communities …